QR код

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Abstract The use of non‐pegylated liposomal doxorubicin (Myocet®) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥5...

Повний опис

Збережено в:
Автори: Juan‐Manuel Sancho, Rubén Fernández‐Alvarez, Francisco Gual‐Capllonch, Esther González‐García, Carlos Grande, Norma Gutiérrez, María‐Jesús Peñarrubia, Ana Batlle‐López, Eva González‐Barca, José‐María Guinea, Eva Gimeno, Francisco‐Javier Peñalver, Miguel Fuertes, Mariana Bastos, José‐Ángel Hernández‐Rivas, José‐María Moraleda, Olga García, Marc Sorigué, Alejandro Martin
Формат: Artigo
Мова:Inglês
Опубліковано: Wiley 2021-02-01
Серія:Cancer Medicine
Предмети:
cardiotoxicity
diffuse large B‐cell lymphoma
liposomal doxorubicin
N‐terminal pro‐B‐type natriuretic peptide
troponin
Онлайн доступ:https://doi.org/10.1002/cam4.3730
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси